Zinc Carnosine: The Gastric Mucosal Protector Backed by Decades of Japanese Research

For more than three decades, doctors in Japan and South Korea have prescribed a single compound for stomach ulcers, gastritis, and the slow erosion of the gastric lining caused by daily anti-inflammatory drugs. The compound is zinc carnosine — a 1:1 chelate of zinc and the dipeptide L-carnosine — and in the U.S. it sits quietly on supplement shelves, largely unknown to the broader market.

The short answer

Zinc carnosine is not the same thing as a standard zinc supplement. It is a chelated molecule that survives stomach acid intact, adheres to inflamed areas of the gastric and intestinal lining, and delivers its two halves — zinc and L-carnosine — locally where mucosal stress is highest. Decades of Japanese clinical work — beginning with its 1994 approval as a gastric ulcer drug under the name polaprezinc — have examined its role in supporting gastric mucosal integrity, blunting NSAID-induced damage, and serving as an adjunct in Helicobacter pylori eradication. A 2007 trial in Gut by Mahmood and colleagues also documented its effect on small-intestinal permeability in volunteers given indomethacin.

In the U.S., zinc carnosine remains a supplement and is not approved as a drug. Nothing here should be read as a claim that it treats, cures, or prevents any disease.

What zinc carnosine actually is

Zinc carnosine is a one-to-one chelate in which a single zinc ion is bonded to a single molecule of L-carnosine, itself a dipeptide of beta-alanine and L-histidine. The molecule is also written as polaprezinc in Japanese pharmacology papers, where it was first developed in the 1980s.

The chelate structure is the reason zinc carnosine behaves differently from ordinary zinc salts. Free zinc ions from gluconate, sulfate, or picolinate are absorbed in the small intestine and circulate systemically. The polaprezinc chelate, by contrast, is poorly soluble in neutral water but unusually adhesive at the slightly acidic pH of damaged mucosa — producing local, slow-release delivery of zinc and L-carnosine to the surface that needs them most.

In 1994, Japan’s Ministry of Health approved polaprezinc as a prescription drug for gastric ulcer under the trade name Promac. South Korea followed. It has been used clinically in Asia for more than thirty years, with post-marketing surveillance covering hundreds of thousands of patients. In the U.S., it is sold as a dietary supplement.

How zinc carnosine appears to work

Three mutually compatible mechanisms appear in the published literature:

• Mucosal adhesion and local delivery. In animal models, radiolabeled polaprezinc binds preferentially to ulcerated gastric tissue and is retained far longer than at intact sites — a depot effect concentrating zinc and L-carnosine over damaged areas.
• Free-radical scavenging. The L-carnosine half is a well-characterized intracellular antioxidant. In cell-culture work it has been shown to quench reactive oxygen species generated during inflammation and to stabilize membrane lipids against peroxidation.
• Anti-H. pylori activity and heat-shock protein induction. Several Japanese groups have published on polaprezinc’s ability to inhibit H. pylori growth in vitro and to induce heat-shock protein 72 in gastric epithelial cells, a protein associated with cytoprotection under stress.

Several mechanisms have been extended from cell-culture and animal work to human gastric biopsy and endoscopic studies. This gives zinc carnosine a more developed mechanistic footprint than most ingredients of its kind. For context, see our overview of intestinal permeability and barrier biology.

What the clinical research shows

The strongest human evidence concentrates in three areas: NSAID-induced GI damage, H. pylori eradication as an antibiotic adjunct, and gastric ulcer healing in the prescription context of Japan and South Korea. A smaller body of work addresses small-intestinal permeability.

NSAID-induced damage. A 2013 randomized trial by Choi in aspirin-treated patients reported reduced endoscopic evidence of gastric mucosal injury with polaprezinc versus placebo. Research has suggested polaprezinc may support gastric mucosal integrity under NSAID use — though it is not a substitute for prescription proton-pump inhibitors when those are clinically indicated.

Gastric ulcer healing. Matsukura 1998 reported endoscopically confirmed ulcer healing rates with polaprezinc as monotherapy or alongside acid-suppressing drugs — the Japanese regulatory trials that underpin the prescription status. In the U.S., zinc carnosine cannot be marketed as an ulcer treatment; patients with diagnosed peptic ulcer disease should be under clinician care.

H. pylori adjunct. Kashimura 1999 and subsequent work examined adding polaprezinc to standard triple-therapy. Across multiple small trials the pattern suggested modest improvement in eradication, particularly in clarithromycin-resistant strains. Watari 2013 summarized this work. See our profile of mastic gum for another ingredient with anti-H. pylori research.

Small-intestinal permeability. The Mahmood 2007 paper in Gut deserves its own line. Healthy volunteers were given indomethacin — an NSAID that acutely increases small-bowel permeability — with or without zinc carnosine. The lactulose/rhamnose ratio rose markedly in the indomethacin-only arm and was substantially blunted in the zinc-carnosine arm. It is a direct demonstration in healthy humans of a supplemental ingredient affecting a measurable permeability marker under challenge, and a frequently-cited paper in leaky-gut research.

Dosing and bioavailability

The most extensively studied regimen is 37.5 mg twice daily, totaling 75 mg per day — delivering roughly 16–17 mg of elemental zinc, slightly above the U.S. RDA (11 mg men, 8 mg women). The tolerable upper intake for elemental zinc is 40 mg/day for adults; chronic higher intake can interfere with copper absorption.

U.S. supplements range from 37.5 to 150 mg total daily. The low end matches the Japanese prescription dose; 150 mg pushes elemental zinc near or above 40 mg when combined with diet and a multivitamin, and is generally the highest dose worth using without clinical supervision.

Taken with food, zinc carnosine is generally well-tolerated. On an empty stomach it can occasionally cause mild nausea. Splitting the dose morning and evening is the standard approach.

Safety and drug interactions

Zinc carnosine has a generally favorable safety record across decades of clinical and post-marketing use in Asia. The most common adverse effects are mild GI symptoms — nausea, occasional constipation, metallic taste — and are uncommon at standard doses.

Three considerations worth flagging:

• Copper depletion at high doses. Zinc and copper share absorptive transporters. Sustained elemental zinc above 40 mg/day has been associated with reduced serum copper. Consider periodic copper status assessment for continuous use at the upper end.
• Chelation with certain antibiotics. The zinc moiety chelates fluoroquinolones and tetracyclines in the gut lumen, reducing antibiotic absorption. Separate zinc-containing supplements from these antibiotics by at least two hours.
• Pregnancy, nursing, and pediatric use. Data are more limited; discuss with a healthcare provider before starting.

Anyone with a diagnosed GI condition — peptic ulcer disease, IBD, GERD — or taking prescription acid-suppressing medication should consult their physician before adding zinc carnosine.

Zinc carnosine vs. zinc picolinate (and other zinc forms)

A common misunderstanding is that zinc carnosine is interchangeable with other zinc supplements. It is not. The research documenting gastric-mucosal effects, NSAID protection, and the Mahmood permeability finding has been done specifically with the polaprezinc chelate — and cannot be assumed to transfer to other forms.

• Zinc gluconate and zinc sulfate — inexpensive, well-absorbed forms for correcting systemic zinc deficiency. No gastric-mucosal-adhesion property.
• Zinc picolinate — a chelate with picolinic acid; well-absorbed for whole-body zinc, but not the same molecule and not carrying the same gut-specific research.
• Zinc bisglycinate — a chelate with two glycine molecules; well-tolerated for systemic zinc support, not equivalent for gut-mucosal purposes.
• Zinc carnosine (polaprezinc) — the specific molecule the gastric-mucosal research has been done on. The carnosine half contributes the antioxidant property; the chelate structure contributes the local-delivery property.

For whole-body zinc nutriture, several forms are reasonable. For the gastric- and small-intestinal-lining application studied in the published literature, zinc carnosine is the form that has been used.

Who may benefit most

Based on the pattern of published evidence, zinc carnosine is most commonly used by people in these contexts:

• People on chronic NSAID therapy (daily low-dose aspirin, or longer-term ibuprofen or naproxen) who want to support gastric mucosal integrity alongside any clinician-prescribed gastroprotection
• People who have completed standard H. pylori eradication and want to support gastric-lining recovery
• People interested in the intersection of intestinal permeability research and supplemental cofactors, often alongside ingredients like L-glutamine
• People building a layered upper-GI regimen that already includes mastic gum and want a second mechanism (chelated zinc + carnosine antioxidant)
• People with diagnosed reflux working with a clinician; see our heartburn and probiotics overview for context

Who probably does not need it: people with no upper-GI symptoms, no NSAID exposure, and no specific reason to target the gastric mucosa. For broad daily microbial support, a multi-strain probiotic with prebiotic fiber is the more conventional starting point. Zinc carnosine layers on top of that foundation for a specific application.

A practical protocol

The regimen most directly mirroring the research is 37.5 mg twice daily with food. The 75 mg daily total delivers roughly 17 mg of elemental zinc and matches the Japanese prescription regimen — a sensible default for adults without contraindications.

• Take it with food. Minimizes nausea and places the chelate in the stomach during peak mucosal stress.
• Separate from antibiotics. If on a fluoroquinolone or tetracycline, take zinc carnosine at least two hours before or after.
• Watch the elemental-zinc total. Add up zinc from your multivitamin and any standalone zinc product. The conservative ceiling is 40 mg/day from supplements.
• Consider a copper buffer for long courses. For continuous use beyond three months, low-dose copper (1–2 mg/day) hedges against zinc-copper antagonism. Many comprehensive formulas already include this.
• Reassess every three to six months. Zinc carnosine is most defensible when there is a clear reason. When that reason resolves, consider whether continued daily use or an episodic approach makes more sense.

For broader terminology, see our gut-health glossary. For acid-reflux questions that often co-occur, our probiotics and acid reflux guide covers what the research does and does not show.

The bottom line

Zinc carnosine is one of the most under-recognized gut-support ingredients in the U.S. market — a prescription drug in Japan and South Korea, with a clinical record spanning three decades. The published research addresses three specific applications: gastric ulcer healing in the prescription context, support of mucosal integrity under NSAID use, and adjunctive use in H. pylori eradication. A smaller body of work addresses small-intestinal permeability under experimental challenge.

What it is not is a casual, general-purpose supplement for vague digestive complaints. It is a specific molecule with a specific mechanism, studied for specific contexts. Zinc carnosine fits best alongside — not in place of — a daily multi-strain probiotic, prebiotic fiber, and broader gut-lining cofactors. For most readers, it is a targeted layer added when there is a clear reason, and reassessed when that reason resolves.